Effector Therapeutics
Solana Beach, US · Founded 2012 · Delaware corporation · 7 known investors
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company. The company is no longer operating.
Founders & leadership
SF
Stephen F. Worland, Ph.D.Executive
AM
Alana McNultyExecutive
Board
SG
Simeon GeorgeBoard director
JR
KH
Ken HaasBoard director
LL
Laurence LaskyBoard director
MG
Markus GoebelBoard director
Investors · 7
Astellas Venture Management LLCSouth San Francisco · $200K – $5M
Mission Bay CapitalSan Francisco
Mission BiocapitalSan Francisco · $500K
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Pfizer Venture Investments$5M – $20M
US Venture PartnersMenlo Park · $500K – $10M
Sofinnova VenturesreportedMenlo Park · $100K – $15Mvia Maha Katabi · board
Reported raises · per SEC filings
Form D private placements$129.4M disclosed across 4 rounds · 2013–2019
▶$20.4MraisedMay 2019 · 25 investors · BiotechnologyRule 506(b)
▶$20.4MraisedMay 2019 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Denis Patrick, Ph.D.Director
- Stephen T. Worland, Ph.D.Executive Officer, Director
- John W. SmitherDirector
- Stefan Larson, Ph.D.Director
- Alana McNultyExecutive Officer
- David Maki, J.D.Director
- Jonathan D. Root, M.D.Director
- Kenneth Haas, J.D.Director
- Simeon J. George, M.D.Director
- Laurence Lasky, Ph.D.Director
- Offering amount
- $21.8M
- Amount sold
- $20.4M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.8MraisedJul 2017 · 26 investors · BiotechnologyRule 506(b)
▶$16.8MraisedJul 2017 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan D. Root, M.D.Director
- Stephen T. Worland, Ph.D.Executive Officer, Director
- Alana McNultyExecutive Officer
- Jeremy Barton, M.D.Executive Officer
- Kenneth Haas, J.D.Director
- Simeon J. George, M.D.Director
- Maha Katabi, Ph.D.Director
- David Maki, J.D.Director
- Markus Goebel, M.D., Ph.D.Director
- Elaine Jones, Ph.D.Director
- Laurence Lasky, Ph.D.Director
- Offering amount
- $38.6M
- Amount sold
- $16.8M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$56MraisedFeb 2016 · 20 investors · BiotechnologyRule 506(b)
▶$56MraisedFeb 2016 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ken HaasDirector
- Maha KatabiDirector
- Simeon GeorgeDirector
- David MakiDirector
- Laurence LaskyDirector
- Markus GoebelDirector
- Stephen T. Worland, Ph.D.Executive Officer, Director
- Alana McNultyExecutive Officer
- Jonathan RootDirector
- Offering amount
- $56M
- Amount sold
- $56M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$36.2MraisedJul 2015 · 15 investors · BiotechnologyRule 506(b)
▶$36.2MraisedJul 2015 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen F. Worland, Ph.D.Executive Officer, Director
- Alana McNultyExecutive Officer
- Simeon GeorgeDirector
- Jonathan RootDirector
- Ken HaasDirector
- Laurence LaskyDirector
- Markus GoebelDirector
- Offering amount
- $57M
- Amount sold
- $36.2M
- First sale
- May 2013
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 10
by search overlap
Actuate Therapeutics7 shared keywordsClinical-stage therapeutics company focusing on high-impact cancers and inflammatory diseases.
Electra Therapeutics5 shared keywordsElectra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment. The company explores and validates novel drug targets with a focus on breakthrough therapies addressing underlying disease pathology.
Fate Therapeutics5 shared keywordsFate Therapeutics develops clinical-stage cell therapy drug candidates for autoimmune diseases and cancer, using an induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered cell products. Its therapies aim to overcome manufacturing and commercialization limitations of conventional cell therapies.
Edgewise Therapeutics5 shared keywordsEdgewise Therapeutics develops novel therapeutics for serious cardiovascular muscle diseases, including hypertrophic cardiomyopathy (HCM) and heart failure. The company focuses on drug development targeting cardiac muscle for patients with life-limiting cardiovascular conditions.
Stoke Therapeutics4 shared keywords
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eureka Therapeutics4 shared keywordsEureka Therapeutics is a clinical-stage biopharmaceutical company developing T-cell-based therapies to treat solid tumors and other cancers. Its pipeline is built on the ARTEMIS and E-ALPHA technology platforms aimed at targeting cancer-specific antigens.
Robinhood4 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Click Therapeutics4 shared keywordsClick Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.
Alector4 shared keywordsAlector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration. The company focuses on patients with neurodegenerative conditions and applies genetics, neuroscience, and immunology to advance new treatments.
Companies competing with Effector Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Effector Therapeutics do?
- eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company. The company is no longer operating.
- Who are Effector Therapeutics's investors?
- Effector Therapeutics's investors include Astellas Venture Management LLC, Mission Bay Capital, Mission Biocapital, OUP (Osage University Partners), Pfizer Venture Investments, US Venture Partners, Sofinnova Ventures.
- How much funding has Effector Therapeutics raised?
- Effector Therapeutics has disclosed $129.4M raised across 4 rounds.
- Where is Effector Therapeutics headquartered?
- Effector Therapeutics is headquartered in Solana Beach, US.